DOCSLIB.ORG

Morphosys AG Mailing Address Business Address SEMMELWEISSTR

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Morphosys AG Mailing Address Business Address SEMMELWEISSTR SECURITIES AND EXCHANGE COMMISSION FORM 6-K Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Filing Date: 2019-02-28 | Period of Report: 2019-02-28 SEC Accession No. 0001193125-19-055826 (HTML Version on secdatabase.com) FILER MorphoSys AG Mailing Address Business Address SEMMELWEISSTR. 7 SEMMELWEISSTR. 7 CIK:1340243| IRS No.: 000000000 | State of Incorp.:2M | Fiscal Year End: 1231 PLANEGG 2M 82152 PLANEGG 2M 82152 Type: 6-K | Act: 34 | File No.: 001-38455 | Film No.: 19640648 49 89 89927-0 SIC: 2834 Pharmaceutical preparations Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF A FOREIGN ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For February 28, 2019 Commission File Number 1-38455 MorphoSys AG Semmelweisstrasse 7 82152 Planegg Germany (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☒ If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Exhibits 99.1 Presentation: Company Update February 2019 Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MORPHOSYS AG (Registrant) Date: February 28, 2019 By: /s/ Jens Holstein Name: Jens Holstein Title: CFO By: /s/ Nicola Thomas Name: Nicola Thomas Title: Specialist Corporate Communications and Investor Relations Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Engineering the Medicines of Tomorrow Company Update February 2019 Exhibit 99.1 Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Thisongoing communication clinical research contains programs certain may forward-looking not support registration statements or concerning further development the MorphoSys of its groupproduct of candidatescompanies, due including to safety its, effinancialficacy or guidance other reasons), for 2018, MorphoSys’ the commencement,s reliance ontiming collaborations and results with of clinical third parties, trials and estimating release ofthe clinical commercial data both potential in respect of its ofdevelopment its proprietary programs product and candidates other risks and indicated of product in thecandidates risk factors of its included collaborators, in MorphoSys’ the developments Registration of commercial Statement capabilities, on Form F-1 in and particular other filings with respect with the to US MOR208, Securities and and the Exchange transition Commission.of MorphoSys Given to a fully these integrated uncertainties, biopharmaceutical the reader is advised company not, tothe place expected any unduetime of reliance launch onof MOR208,such forward-looking interaction withstatements. regulators, These including forward-looking the potential statements approval speak of MorphoSys’ only as of thes current date of or publication future drug of candidates, this document. including MorphoSys discussions expressly with thedisclaims FDA regarding any obligation the potential to update approval any such to marketforward-looking MOR208, statements and expected in this royalty document and milestone to reflect payments any change in connectionin its expectations with MorphoSys’ with regards collaborations.thereto or any change The forward-looking in events, conditions statements or circumstances contained herein on which represent any thesuch judgment statement of is MorphoSys based or that as mayof the af datefect ofthe this likelihood release andthat involveactual results known will and dif unknownfer from risksthose and set uncertainties,forth in the forward-looking which might cause statements, the actual unless results, specifically financial required condition by and law liquidity or regulation., performance The compounds or achievements discussed of in MorphoSys, this slide presentation or industry areresults, investigational to be materially products different being from developed any historic by MorphoSys or future results,and its partnersfinancial and conditions are not currentlyand liquidity approved, performance by the U.S. or achievements Food and Drug expressed Administration or implied (FDA), by such European forward-looking Medicine Agencystatements. (EMA) In addition, or any other even regulatoryif MorphoSys’ authoritys results, (except performance, for guselkumab/T financialremfya®). condition Thisand liquidity presentation, and includesthe development forward-looking of the industry statements. in which © MorphoSys it operates AG,are consistent February 2019with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys’s expectations regarding its 2018 results of operations may be incorrect, MorphoSys’s expectations regarding its development programs may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that MorphoSys may fail to obtain regulatory approval for MOR208 and that data from MorphoSys’s Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document © MorphoSys AG, February 2019 Investment Highlights Proprietary Technology Platforms Proven antibody capability Novel antibody-based and peptide formats MOR208 FDA breakthrough therapy designation for lenalidomide combination in r/r DLBCL Planned regulatory filing in 2019 MOR106, MOR202, MOR103, MOR210 Differentiated product candidates from proprietary development activities MorphoSys US Inc. Preparing for U.S. commercialization of MOR208 Broad Clinical Pipeline Proprietary and partnered clinical pipeline: 29 product candidates Tremfya® First-in-class anti-IL-23 antibody provides strongly growing royalty stream Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document * Phase 1 in healthy volunteers completed; currently in preclinical investigation 29 Product Candidates in Clinical Development, One Product Launched © MorphoSys AG, February 2019 Our Clinical Pipeline Program Partner Target Disease area Phase 1 Phase 2 Phase 3 Launched Tremfya® (guselkumab) Janssen IL-23p19 Psoriasis Gantenerumab Roche Amyloid-ß Alzheimer’s disease MOR208 - CD19 Hematological malignancies Anetumab ravtansine (BAY94-9343) Bayer Mesothelin (ADC) Solid tumors BAY1093884 Bayer TFPI Hemophilia BHQ880 Novartis DKK-1 Multiple myeloma Bimagrumab (BYM338) Novartis ActRIIB Metabolic diseases CNTO6785 Janssen - Inflammation Ianalumab (VAY736) Novartis BAFF-R Inflammation MOR103/GSK3196165 GSK GM-CSF Inflammation MOR106 Novartis/Galapagos IL-17C Inflammation MOR202 I-Mab Biopharma CD38 Multiple myeloma NOV-12 (MAA868) Novartis Factor XI Prevention of thrombosis Setrusumab (BPS804) Mereo/Novartis Sclerostin Brittle bone syndrome Tesidolumab (LFG316) Novartis C5 Eye diseases Utomilumab (PF-05082566) Pfizer 4-1BB Cancer Xentuzumab (BI-836845) BI IGF-1 Solid tumors BAY2287411 Bayer Mesothelin Cancer Elgemtumab (LJM716) Novartis HER3 Cancer MOR107 (LP2-3)* - AT2-R Not disclosed NOV–7 (CLG561) Novartis - Eye diseases NOV–8 Novartis - Inflammation NOV-9 (LKA651) Novartis - Diabetic eye diseases NOV-10 (PCA062) Novartis - Cancer NOV-11 Novartis - Blood disorders NOV-13 (HKT288) Novartis - Cancer NOV-14 Novartis - Asthma PRV-300 (CNTO3157) ProventionBio TLR-3 Inflammation Vantictumab (OMP-18R5) OncoMed Fzd 7 Solid tumors 2 12 14 Partnered Discovery Programs Proprietary Development Programs Out-licensed Proprietary Development Programs Most advanced development stage Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Proprietary Development Programs © MorphoSys AG, February 2019 Copyright © 2019 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document * For Development in China, Hong Kong, Macao, Taiwan and (MOR210 only) South Korea ** A phase 1 study in healthy volunteers was completed; currently in preclinical investigation © MorphoSys AG, February 2019 Portfolio of Proprietary Development Segment Program Partner Target Disease area Preclinical Phase 1 Phase 2 Phase 3 MOR208 - CD19 DLBCL (B-MIND) DLBCL (L-MIND) CLL (COSMOS) MOR202 I-Mab Biopharma* CD38 Multiple myeloma MOR106 Novartis/ Galapagos IL-17C Atopic dermatitis (iv) Atopic dermatitis (sc) MOR103/ GSK3196165 GSK GM-CSF Inflammation MOR107** - AT2-R Oncology under investigation MOR210 I-Mab Biopharma* C5aR Oncology 6 proprietary or co-developed programs in discovery Proprietary
Load more

Recommended publications
  • Anetumab Ravtansine
    June 2016 Company Update Safe Harbor This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing. These and other risks and uncertainties are detailed in the Company’s Annual Report. © MorphoSys AG, Company Update - June 2016 2 MorphoSys at a Glance MorphoSys is developing a pipeline of truly differentiated therapeutic antibodies built using proprietary technologies Munich, Germany-based biopharmaceutical company The industry’s largest antibody therapeutic pipeline assembled using proprietary technologies: 104 active therapeutic programs 26 antibodies in clinical trials Growing portfolio of attractive proprietary assets Strong balance sheet with recurring cash-flows supports growing investment in R&D Successful track-record of partnering world-wide Listed on the German TecDAX © MorphoSys AG, Company Update - June 2016 3 The MorphoSys Pipeline 26 Clinical Product Candidates, 104 Total Most advanced development stage Program Partner Target Disease Area Discovery Preclinic Phase 1 Phase 2 Phase 3 Bimagrumab (BYM338) Novartis ActRIIB Musculoskeletal diseases Guselkumab (CNTO1959) Janssen IL23p19 Psoriasis Gantenerumab Roche Amyloid-ß Alzheimer’s disease MOR208 - CD19 ALL, CLL, NHL MOR202 - CD38 Multiple myeloma MOR103/GSK3196165 GSK GM-CSF Inflammation
    [Show full text]
  • 9.0 Bn 23 000 200 +
    42 | Novartis Annual Report 2017 Innovation The Novartis Institutes for BioMedical Research works in concert with our Global Drug Development group to bring innovative treatments to patients around the world. In 2017, we advanced our drug discovery and development efforts by encouraging greater collaboration and out-of-the-box thinking, exploring new approaches that could improve how we work, and investing in promising tools and technologies. We made progress in priority disease areas with high unmet medical needs. We also marked several key milestones, including US FDA approval – the first of its kind – for a type of personalized cell therapy that could change the course of cancer care. 9.0 bn 23 000 200 + Research and development Scientists, physicians and business Projects in clinical development spending in 2017, amounting to professionals working in research 18.3% of net sales (USD) and development worldwide Collaborative Efficient, effective Progress in important science drug development disease areas We are increasing collaboration We are using digital technology We highlight areas of our work where in research as we try to leverage and data analysis to make drug we are driving significant innovation, innovation from a variety of sources. development swifter and more or where we can potentially have an We are also exploring ways to effective. And we are taking steps important impact on patients and harness digital technology in drug to strengthen our pipeline. public health. discovery, as well as new therapeutic k page 46 k Immuno-oncology page 48 approaches such as cell therapies. k Multiple sclerosis page 50 k page 43 k Liver disease page 52 k Ophthalmology page 53 k Asthma page 55 k Malaria page 56 INNOVATION Novartis Annual Report 2017 | 43 Discovery For new treatments, the journey from laboratory to patient Promoting open innovation starts in the discovery phase where researchers try to Our efforts to increase the flow of ideas between identify potentially groundbreaking therapies.
    [Show full text]
  • Stock Price Effects of Breakthrough Therapy Designation
    NEWS & ANALYSIS SUPPLEMENTARY INFORMATION BIOBUSINESS BRIEFS In format as provided by the authors Stock price effects of breakthrough therapy designation David Hoffmann, Shane Van Dalsem and Frank S. David NATURE REVIEWS | D RU G D IS COVERY Supplementary Box 1 | Methods and data 1. Methods 1a. Sample definition and data collection Event data collection The website Friends of Cancer Research (http://www.focr.com/) lists all publicly available Breakthrough Therapy Designations (BTD), which were downloaded with a cut-off on 06/30/18. For partnered products, we treated each partner as if it had independently received the BTD, and thus generated an entry for each co-developing company. For each BTD, we identified the original press release and excluded companies that did not disclose the exact BTD announcement date. Further, we excluded companies that are not publicly traded on a US stock exchange, and those that had incomplete stock price data in the event period (as of 08/24/18). We also excluded BTDs that coincided with major corporate press releases (e.g., quarterly results or clinical trial news). In cases where the same company announced several BTDs on the same date, we retained only one for analysis. This yielded 146 BTDs (102 commercial, 44 pre-commercial). Subsequently, we identified three outliers and excluded them from the final CAAR analysis (see later section). 1 Stock price collection The historical closing stock prices (unadjusted) for the range of -111 days to +90 days around the disclosure of the BTD events were downloaded from https://finance.yahoo.com/. Historical stock prices from delisted companies were downloaded from https://amigobulls.com or https://barchart.com.
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • Tables-Of-Phase-3-Mabs.Pdf
    Table 3. Monoclonal antibodies in Phase 2/3 or 3 clinical studies for cancer indications Most advanced Primary sponsoring company INN or code name Molecular format Target(s) phase Phase 3 indications Therapeutic area Janssen Research & Development, LLC JNJ-56022473 Humanized mAb CD123 Phase 2/3 Acute myeloid leukemia Cancer Murine IgG1, Actinium Pharmaceuticals Iomab-B radiolabeled CD45 Phase 3 Acute myeloid leukemia Cancer Humanized IgG1, Seattle Genetics Vadastuximab talirine ADC CD33 Phase 3 Acute myeloid leukemia Cancer TG Therapeutics Ublituximab Chimeric IgG1 CD20 Phase 3 Chronic lymphocytic leukemia Cancer Xencor XMAB-5574, MOR208 Humanized IgG1 CD19 Phase 2/3 Diffuse large B-cell lymphoma Cancer Moxetumomab Murine IgG1 dsFv, AstraZeneca/MedImmune LLC pasudotox immunotoxin CD22 Phase 3 Hairy cell leukemia Cancer Humanized scFv, Viventia Bio Oportuzumab monatox immunotoxin EpCAM Phase 3 Bladder cancer Cancer scFv-targeted liposome containing Merrimack Pharmaceuticals MM-302 doxorubicin HER2 Phase 2/3 Breast cancer Cancer MacroGenics Margetuximab Chimeric IgG1 HER2 Phase 3 Breast cancer Cancer Gastric cancer or gastroesophageal junction Gilead Sciences GS-5745 Humanized IgG4 MMP9 Phase 3 adenocarcinoma; ulcerative colitis (Phase 2/3) Cancer; Immune-mediated disorders Depatuxizumab Humanized IgG1, AbbVie mafodotin ADC EGFR Phase 2/3 Glioblastoma Cancer AstraZeneca/MedImmune LLC Tremelimumab Human IgG2 CTLA4 Phase 3 NSCLC, head & neck cancer, bladder cancer Cancer NSCLC, head & neck cancer, bladder cancer, breast AstraZeneca/MedImmune
    [Show full text]
  • Targeting Costimulatory Molecules in Autoimmune Disease
    Targeting costimulatory molecules in autoimmune disease Natalie M. Edner1, Gianluca Carlesso2, James S. Rush3 and Lucy S.K. Walker1 1Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF 2Early Oncology Discovery, Early Oncology R&D, AstraZeneca, Gaithersburg, MD, USA 3Autoimmunity, Transplantation and Inflammation Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland *Correspondence: Professor Lucy S.K. Walker. Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF. Tel: +44 (0)20 7794 0500 ext 22468. Email: [email protected]. 1 Abstract Therapeutic targeting of immune checkpoints has garnered significant attention in the area of cancer immunotherapy, and efforts have focused in particular on the CD28 family members CTLA-4 and PD-1. In autoimmunity, these same pathways can be targeted to opposite effect, to curb the over- exuberant immune response. The CTLA-4 checkpoint serves as an exemplar, whereby CTLA-4 activity is blocked by antibodies in cancer immunotherapy and augmented by the provision of soluble CTLA-4 in autoimmunity. Here we review the targeting of costimulatory molecules in autoimmune disease, focusing in particular on the CD28 family and TNFR family members. We present the state-of-the-art in costimulatory blockade approaches, including rational combinations of immune inhibitory agents, and discuss the future opportunities and challenges in this field. 2 The risk of autoimmune disease is an inescapable consequence of the manner in which the adaptive immune system operates. To ensure effective immunity against a diverse array of unknown pathogens, antigen recognition systems based on random gene rearrangement and mutagenesis have evolved to anticipate the antigenic universe.
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • View the Whitepaper
    Aging and Sarcopenia Frailty is generally understood as a progressive age-related decline in physiological systems that results in decreased reserves, increasing risk for poor health outcomes including falls, incident disability, hospitalization, and mortality1. There are however two distinct concepts that emerge from the clinical and research literature. The first is of a syndrome associated with underlying physiological and metabolic changes that are responsible for driving progressive physical and cognitive impairments through to loss of functional capacity, often helped on the way by acute or chronic disease or injury. As a result, the frail person is at increased risk of disability or death from minor external stresses.2,3.The second concept underpins a pragmatic approach, which treats frailty as a collection of risk factors for future adverse events, while not necessarily bearing a direct pathophysiological relationship to these outcomes. As discussed later these positions are not incompatible.23 Another age-related process is sarcopenia, a term suggested by Rosenberg for the well- recognized loss of muscle with ageing - major component of frailty. The diagnosis, treatment and prevention of sarcopenia is recommended to become part of routine clinical practice. Skeletal muscle accounts for a third or more of total body mass4. Along with movement, muscle plays a key role in temperature regulation and metabolism, as muscle is a reservoir for proteins and energy that can be used for the synthesis of antibodies and gluconeogenesis.2 Low muscle mass is associated with poor outcomes from acute illness, probably because of the reduced metabolic reserve. Sarcopenia is an accelerated loss of muscle mass with decreased function, associated with an increase in falls, functional decline, frailty, and increased mortality.
    [Show full text]
  • Prescrire's Contribution to the WHO Consultation List
    World Health Organization Raffaella Balocco INN Programme Manager Quality Assurance & Safety : Medecines CH 1211 GENEVA 27 SUISSE Paris, November 2, 2017 Prescrire’s contribution to the WHO consultation on List 117 of proposed INNs Prescrire is an independent continuing education organisation for healthcare professionals. It is wholly funded by its subscribers, carries no advertising, and receives no other financial support whatsoever. Both independently since 1981, and with others as part of the Medicines in Europe Forum, the International Society of Drug Bulletins (ISDB) and the International Medication Safety Network (IMSN), Prescrire has been advocating the systematic use by healthcare professionals and patients of international nonproprietary names (INNs), which are clearer, safer and more informative than drug brand names (1-6). Making INNs safer. The principles underlying the creation of INNs are the same that apply to the prevention of medication errors: standardisation, differentiation, and facilitation of logic and redundancy checks (7). However, even with the INN system there is a residual risk of confusion, partly owing to the sheer number of INNs now in circulation. A report from the Council of Europe, which recommends the use of INNs, calls for active participation in the public consultations on proposed INNs organised by the World Health Organization (WHO), in order to identify any risk of confusion during their clinical use (8). Our review group, consisting of members of Prescrire’s editorial staff, including hospital- and community-based health professionals, joined by lecturers in pharmacy and medicine and health professionals from two university hospitals, has examined List 117 in order to participate in the public consultation on this latest list of proposed INNs, published in July 2017 (a)(9).
    [Show full text]
  • A Vicious Cycle of Osteosarcopenia in Inflammatory Bowel Diseases
    nutrients Review A Vicious Cycle of Osteosarcopenia in Inflammatory Bowel Diseases—Aetiology, Clinical Implications and Therapeutic Perspectives Dorota Skrzypczak *, Alicja Ewa Ratajczak , Aleksandra Szymczak-Tomczak, Agnieszka Dobrowolska , Piotr Eder and Iwona Krela-Ka´zmierczak* Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, 49 Przybyszewskiego Street, 60-355 Poznan, Poland; [email protected] (A.E.R.); [email protected] (A.S.-T.); [email protected] (A.D.); [email protected] (P.E.) * Correspondence: [email protected] (D.S.); [email protected] (I.K.-K.) Abstract: Sarcopenia is a disorder characterized by a loss of muscle mass which leads to the reduction of muscle strength and a decrease in the quality and quantity of muscle. It was previously thought that sarcopenia was specific to ageing. However, sarcopenia may affect patients suffering from chronic diseases throughout their entire lives. A decreased mass of muscle and bone is common among patients with inflammatory bowel disease (IBD). Since sarcopenia and osteoporosis are closely linked, they should be diagnosed as mutual consequences of IBD. Additionally, multidirectional treatment of sarcopenia and osteoporosis including nutrition, physical activity, and pharmacotherapy should include both disorders, referred to as osteosarcopenia. Keywords: sarcopenia; IBD; Crohn’s disease; ulcerative colitis; malnutrition; low muscle mass; low muscle strength; nutritional therapy Citation: Skrzypczak, D.; Ratajczak, A.E.; Szymczak-Tomczak, A.; Dobrowolska, A.; Eder, P.; Krela-Ka´zmierczak, I. A Vicious Cycle 1. Introduction of Osteosarcopenia in Inflammatory Bowel Diseases—Aetiology, Clinical Sarcopenia is a syndrome associated with a reduction of skeletal muscle mass, leading Implications and Therapeutic to decreased muscle strength [1].
    [Show full text]
  • Monoclonal Antibodies As Neurological Therapeutics
    pharmaceuticals Review Monoclonal Antibodies as Neurological Therapeutics Panagiotis Gklinos 1 , Miranta Papadopoulou 2, Vid Stanulovic 3, Dimos D. Mitsikostas 4 and Dimitrios Papadopoulos 5,6,* 1 Department of Neurology, KAT General Hospital of Attica, 14561 Athens, Greece; [email protected] 2 Center for Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 11527 Athens, Greece; [email protected] 3 Global Pharmacovigilance, R&D Sanofi, 91385 Chilly-Mazarin, France; vid.stanulovic@sanofi.com 4 1st Neurology Department, Aeginition Hospital, National and Kapodistrian University of Athens, 11521 Athens, Greece; [email protected] 5 Laboratory of Molecular Genetics, Hellenic Pasteur Institute, 129 Vasilissis Sophias Avenue, 11521 Athens, Greece 6 Salpetriere Neuropsychiatric Clinic, 149 Papandreou Street, Metamorphosi, 14452 Athens, Greece * Correspondence: [email protected] Abstract: Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological conditions with diverse pathophysio- logical mechanisms, including multiple sclerosis, migraines and neuromuscular disease. In addition, a great number of monoclonal antibodies against several targets are being investigated for many more neurological diseases, which reflects our advances in understanding the pathogenesis of these
    [Show full text]
  • AHRQ Healthcare Horizon Scanning System – Status Update
    AHRQ Healthcare Horizon Scanning System – Status Update Horizon Scanning Status Update: January 2014 Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA290201000006C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 January 2014 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290201000006C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. A novel intervention may not appear in this report simply because the System has not yet detected it. The list of novel interventions in the Horizon Scanning Status Update Report will change over time as new information is collected. This should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual target technology reports are developed for those that appear to be closer to diffusion into practice in the United States. A representative from AHRQ served as a Contracting Officer’s Technical Representative and provided input during the implementation of the horizon scanning system. AHRQ did not directly participate in the horizon scanning, assessing the leads or topics, or provide opinions regarding potential impact of interventions.
    [Show full text]